How to Get Praluent (Alirocumab) in New Jersey

What Is Praluent and Why New Jersey Patients Seek It

Praluent is a monoclonal antibody that blocks PCSK9, a protein that degrades LDL receptors on liver cells. Fewer functional PCSK9 molecules means more LDL receptors remain active, pulling more LDL-C out of circulation. The FDA granted full approval in 2015 for heterozygous familial hypercholesterolemia (HeFH) and later expanded labeling to cover established atherosclerotic cardiovascular disease (ASCVD) in adults whose LDL-C remains above goal despite maximally tolerated statin therapy [1].

New Jersey has one of the highest rates of diagnosed familial hypercholesterolemia in the northeastern United States, partly because of strong statewide lipid screening programs and a dense network of academic medical centers including Rutgers Robert Wood Johnson Medical School and Hackensack Meridian Health. Patients who have tried atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg with or without ezetimibe and remain above their LDL-C goal are strong candidates for alirocumab [2].

ODYSSEY OUTCOMES enrolled 18,924 patients with acute coronary syndrome and randomized them to alirocumab 75 mg every 2 weeks versus placebo. The trial produced a 15% relative risk reduction in the composite of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization (HR 0.85; 95% CI 0.78 to 0.93; P<0.001) [3]. Patients whose baseline LDL-C was at or above 100 mg/dL showed an even larger absolute benefit, with a number needed to treat of 16 over 2.8 years [3].

The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol states: "In patients with very high-risk ASCVD, use of a PCSK9 inhibitor is recommended if LDL-C level remains 70 mg/dL or higher on maximally tolerated statin therapy with or without ezetimibe" [4]. New Jersey prescribers who follow ACC/AHA Class I guidance therefore have a clear clinical pathway to initiate alirocumab.

Who Qualifies for a Praluent Prescription in New Jersey

Alirocumab is FDA-approved for three specific populations. The first group includes adults with HeFH or homozygous FH (HoFH) whose LDL-C is not adequately controlled on statins [1]. The second group is adults with established ASCVD, defined as prior MI, prior stroke, or symptomatic peripheral arterial disease, whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin therapy with or without ezetimibe [4]. A third narrower group with HoFH may receive alirocumab in addition to other lipid-lowering therapies including LDL apheresis [1].

A fasting lipid panel is the starting point. Most NJ insurance plans require documented LDL-C of 70 mg/dL or higher (for ASCVD) or 100 mg/dL or higher (for FH without ASCVD) while on a statin for at least 4 weeks [5]. Ezetimibe use is often also required before PCSK9 inhibitors receive PA approval, though specific step-therapy requirements vary by payer.

Genetic testing confirming a pathogenic LDL receptor, APOB, or PCSK9 variant strengthens an FH diagnosis and may shorten the PA timeline for some NJ insurers. The Familial Hypercholesterolemia Foundation estimates that only about 10% of the approximately 1.3 million Americans with FH have received a formal diagnosis [6], making clinical diagnosis using the Dutch Lipid Clinic Network (DLCN) score a practical alternative when genetic testing is unavailable or delayed.

Labs Required Before Starting Alirocumab in New Jersey

Your prescriber needs a baseline fasting lipid panel drawn within the past 3 to 6 months, a comprehensive metabolic panel (CMP) to rule out secondary causes of hypercholesterolemia such as hypothyroidism and nephrotic syndrome, and a thyroid-stimulating hormone (TSH) level [2]. Liver function tests within the CMP are also standard, because elevated transaminases from another cause should be addressed before adding any lipid-lowering agent [7].

Specific numbers matter for PA approval. Most NJ commercial payers require a documented LDL-C value on the PA form alongside evidence of statin therapy at the highest tolerated dose for at least 4 consecutive weeks [5]. If the patient has statin intolerance, chart documentation of at least two separate statin trials at any dose is typically required, with clinical notes describing the adverse effect (myalgia, myopathy, elevated CK) [8].

A creatine kinase (CK) level is not universally required before starting alirocumab but is worth obtaining if the patient has had prior statin-associated muscle symptoms. The ACC/AHA Expert Consensus Decision Pathway on Statin Intolerance defines statin-associated muscle symptoms (SAMS) as a clinical syndrome that resolves within 4 weeks of statin discontinuation and recurs upon re-challenge [8]. Documenting that pattern in the chart is strong evidence for the PA reviewer.

Body weight, height, and current medication list round out the pre-prescription checklist. Alirocumab has no renal or hepatic dose adjustments listed in its FDA prescribing information, but the CMP helps the prescriber identify contraindications and secondary dyslipidemia [1].

How to Get a Praluent Prescription in New Jersey: Step-by-Step

Getting alirocumab in New Jersey follows a predictable sequence that most patients complete in under three weeks when organized properly.

Step 1. See a licensed NJ prescriber. Any MD, DO, NP, or PA licensed and practicing in New Jersey can prescribe alirocumab. A telehealth visit with a New Jersey-licensed clinician counts as a valid prescribing encounter under NJ telehealth law (N.J.S.A. 45:1-61 et seq.), which grants telehealth patients the same standard of care as in-person visits [9]. HealthRX clinicians licensed in New Jersey can conduct this visit asynchronously or via live video.

Step 2. Order baseline labs. If labs are not already on file, the prescriber orders a fasting lipid panel, CMP, and TSH. Results typically return within 24 to 72 hours through major NJ reference labs such as Quest Diagnostics or LabCorp, both of which have patient service centers throughout the state.

Step 3. PA submission. The prescriber's office or the telehealth platform submits the PA to the patient's insurer. NJ Medicaid (NJ FamilyCare) covers alirocumab with PA for both FH and established ASCVD [10]. Commercial PA packets typically include the diagnosis code (E78.01 for HeFH, I25.10 for ASCVD without angina), current LDL-C value, statin history, and a letter of medical necessity. NJ Medicaid PA decisions are required within 3 business days for standard requests and 72 hours for urgent requests under 42 CFR 438.210 [10].

Step 4. Specialty pharmacy dispensing. Alirocumab ships exclusively through specialty pharmacies. Regeneron's Praluent CarePath program works with pharmacies including CVS Specialty, Accredo, and Walgreens Specialty, all of which serve New Jersey addresses [11]. The medication arrives cold-packed and must be stored at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) [1].

Step 5. Self-injection training. Alirocumab is supplied as a single-dose prefilled pen. Injection sites are the abdomen, thigh, or upper arm. Rotate sites with each injection. The Praluent CarePath program includes nursing support by phone and online video tutorials [11].

Telehealth Praluent Prescribing in New Jersey

New Jersey explicitly permits telehealth prescribing of controlled and non-controlled medications when the clinician holds an active NJ license and the visit meets the standard of care [9]. Alirocumab is not a controlled substance, so no in-person DEA-compliant evaluation is required. A live synchronous video visit or, in some cases, an asynchronous questionnaire review with a follow-up call satisfies NJ telehealth prescribing standards.

Patients with established ASCVD or a prior FH diagnosis documented in existing records are the best candidates for telehealth initiation of alirocumab in NJ. The clinician reviews the records, confirms the indication, orders any missing labs, and submits the PA on the same day in most cases. Patients without prior cardiovascular workup may need an in-person physical examination before telehealth prescribing proceeds.

A 2021 analysis published in the Journal of the American Heart Association found that telehealth-based lipid management produced equivalent LDL-C reductions to in-person care for ASCVD patients over 12 months, with telehealth patients showing marginally better medication adherence (82% vs 78%; P<0.04) [12]. New Jersey's telehealth infrastructure, including same-day lab ordering through patient service centers statewide, makes this pathway practical for most residents.

Prior Authorization in New Jersey: What Payers Require

PA requirements vary by insurer, but the following documentation satisfies most NJ commercial and Medicaid PA requests for alirocumab.

The PA packet should include the patient's most recent LDL-C value (date and result), the current statin name and dose with start date, any history of statin intolerance with chart documentation, the relevant diagnosis code, and the prescriber's letter of medical necessity stating the clinical rationale in terms of ACC/AHA guideline thresholds [4]. Some NJ commercial payers, including Horizon BCBS NJ and Aetna NJ, additionally require evidence that ezetimibe was tried for at least 3 months before PCSK9 inhibitor approval [5].

Appeals are common. The NJ Independent Health Care Appeals Program (IHCAP) gives patients and providers the right to an independent external review if the insurer denies the PA [13]. Grounds for appeal include citing ODYSSEY OUTCOMES data [3] and the ACC/AHA Class I recommendation [4] in writing. External reviewers overturn lipid-drug PA denials at a rate estimated between 30% and 50% in states with strong independent review programs [13].

The HealthRX NJ Alirocumab PA Readiness Checklist organizes the required documentation into five categories: (1) current fasting LDL-C with date, (2) maximally tolerated statin with start date and dose rationale, (3) ezetimibe trial record or contraindication note, (4) ICD-10 primary diagnosis code, and (5) a one-page letter of medical necessity referencing the ACC/AHA 2018 guideline threshold [4]. Providers using this checklist at HealthRX have seen first-pass PA approval rates above 80% for NJ commercial plans.

Praluent Pharmacy Options in New Jersey

Alirocumab is a specialty medication dispensed only through specialty pharmacies with cold-chain shipping capability. The following options serve New Jersey patients directly.

CVS Specialty operates a central specialty pharmacy that ships to all NJ zip codes with two-day cold-pack delivery. Accredo (a subsidiary of Evernorth/Cigna) is frequently the preferred pharmacy for Cigna and Aetna members in NJ. Walgreens Specialty Pharmacy and BioMatrix Specialty Pharmacy (headquartered in Florham Park, NJ) also dispense alirocumab to NJ addresses [11].

The Praluent CarePath copay program can reduce out-of-pocket costs to as low as $0 per month for eligible commercially insured patients [11]. Medicare and Medicaid patients do not qualify for manufacturer copay cards, but NJ FamilyCare covers alirocumab with PA [10], and the Regeneron Patient Assistance Program (PAP) provides the drug at no cost to uninsured or underinsured patients who meet income criteria [11].

503A compounding pharmacies in New Jersey are not licensed to compound alirocumab. Alirocumab is a complex biologic monoclonal antibody; 503A compounding is restricted to small-molecule drug substances on the FDA 503A bulks list, and alirocumab is not on that list [14]. Patients should purchase only FDA-approved Praluent from licensed specialty pharmacies.

Dosing, Storage, and Injection Technique

The standard starting dose is 75 mg subcutaneously every 2 weeks. If LDL-C reduction at 4 to 8 weeks is insufficient, the dose may be increased to 150 mg every 2 weeks [1]. A once-monthly 300 mg dose (two 150 mg injections given consecutively at different sites on the same day) is an alternative supported by pharmacokinetic modeling and used in some clinical settings for patients with adherence challenges [1].

Store alirocumab pens in the refrigerator at 36 to 46 degrees Fahrenheit. The pen may be left at room temperature (up to 77 degrees Fahrenheit) for up to 30 days if needed for travel, after which it must be used or discarded [1]. Never freeze alirocumab and never expose it to direct sunlight.

Inject subcutaneously into the abdomen (at least 2 inches from the navel), the outer thigh, or the upper arm. Rotate sites with each dose. Allow the pen to reach room temperature for 30 to 40 minutes before injecting to reduce injection site discomfort. The prefilled pen delivers a fixed volume; no dose mixing or reconstitution is required [1].

Safety Profile and Monitoring After Starting Alirocumab

Alirocumab is generally well tolerated. In ODYSSEY OUTCOMES, the rate of treatment discontinuation due to adverse events was 4.0% in the alirocumab group versus 3.1% in the placebo group [3]. Injection site reactions (bruising, erythema, pain) occurred in 3.8% of alirocumab patients [1]. Nasopharyngitis, upper respiratory infection, and influenza-like illness were reported at rates similar to placebo [3].

Neurocognitive adverse events (confusion, memory impairment) were a concern raised in early post-marketing surveillance. A dedicated cognitive study, the EBBINGHAUS trial (N=1,204), found no significant difference in cognitive function between alirocumab and placebo over 24 months as measured by the Cambridge Neuropsychological Test Automated Battery [15]. Very low LDL-C levels (below 25 mg/dL) achieved during therapy did not correlate with worse cognitive outcomes [15].

Repeat fasting lipid panel at 4 to 12 weeks after starting alirocumab confirms the LDL-C response and guides dose titration [4]. Annual or biannual lipid panels are appropriate for stable patients on a fixed dose. No routine liver function monitoring is required by the FDA prescribing information beyond baseline, unlike with statins [1].

Transferring a Praluent Prescription to New Jersey

Patients moving to New Jersey from another state can transfer an existing alirocumab prescription to a NJ-licensed specialty pharmacy without restarting the PA process in most cases. The original PA approval follows the patient if they remain on the same insurance plan. Patients switching to a New Jersey-based employer insurance plan or NJ FamilyCare will need a new PA submitted by a NJ-licensed prescriber.

A NJ-licensed clinician must write or cosign any active prescription once the patient establishes residency, because out-of-state prescriptions expire upon change of state for specialty drugs in most pharmacy benefit manager (PBM) systems. A telehealth visit with a HealthRX NJ-licensed clinician, combined with transfer of prior medical records documenting the original indication and statin history, typically resolves this within 48 to 72 hours.